Asides

Merck Eprova and Isofol Medical Enter Exclusive Agreement for Merck Eprova’s Modufolin® in oncology

• Leucovorin has been a mainstay of colorectal cancer treatment for 50 years • Modufolin® may offer an improved profile over leucovorin in cancer therapy • New licensing deal will allow clinical trials to begin later this year Schaffhausen/ Switzerland, November 11, 2009 – Today Merck Eprova AG announced that the company has signed an …

Merck Eprova and Isofol Medical Enter Exclusive Agreement for Merck Eprova’s Modufolin® in oncology Read More »

Cancer treatment with blockbuster potential

Investerarbolaget Yield med fokus på bolag i Göteborgsregionen har köpt in sig i medicinbolaget Isofol Medical AB. Yield har köpt aktier av Isofols ägare samt i en riktad nyemission. Yields styrelse gör bedömningen att Isofols behandlingsmetod för olika cancersjukdomar, främst så kallad kolorektalcancer, (tjocktarms- och ändtarmscancer) ska utvecklas till en ny svensk internationell storsäljare. Isofol …

Cancer treatment with blockbuster potential Read More »

Scroll to Top